Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

American Heart Journal

Volumn 206, Issue , 2018, Pages 11-23

  Cannon, Christopher P ^a   McGuire, Darren K ^b   Pratley, Richard ^c   Dagogo Jack, Sam ^d   Mancuso, James ^e   Huyck, Susan ^f   Charbonnel, Bernard ^g   Shih, Weichung J ^h   Gallo, Silvina ^e   Masiukiewicz, Urszula ^e   Golm, Gregory ^f   Cosentino, Francesco ⁱ   Lauring, Brett ^f   Terra, Steven G ^e  

^a HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c FLORIDA HOSPITAL   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e PFIZER INC   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g UNIVERSITÉ DE NANTES   (France)

^h RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ERTUGLIFLOZIN; HEMOGLOBIN A1C; PLACEBO; 5-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-1-HYDROXYMETHYL-6,8-DIOXABICYCLO(3.2.1)OCTANE-2,3,4-TRIOL; FUSED HETEROCYCLIC RINGS; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BRAIN ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MODERATE RENAL IMPAIRMENT; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; ADMINISTRATION AND DOSAGE; BLOOD; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; EUROPE; FOLLOW UP; GLUCOSE BLOOD LEVEL; INCIDENCE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; UNITED STATES;

ADULT; AGED; BLOOD GLUCOSE; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EUROPE; FEMALE; FOLLOW-UP STUDIES; GLYCATED HEMOGLOBIN A; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 85054182182     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2018.08.016     Document Type: Article

References (30)

1. Sarwar, N., Gao, P., Seshasai, S.R., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375 (2010), 2215–2222.
2. Roger, V.L., Go, A.S., Lloyd-Jones, D.M., et al. Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. Circulation 123 (2011), e18–e209.
3. Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
4. Bhatt, D.L., Bonaca, M.P., Bansilal, S., et al. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J Am Coll Cardiol 67 (2016), 2732–2740.
5. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
6. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
7. Raz, I., Mosenzon, O., Bonaca, M.P., et al. DECLARE-TIMI 58: Participants’ baseline characteristics. Diabetes Obes Metab 20 (2018), 1102–1110.
8. Terra, S.G., Focht, K., Davies, M., et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab 19 (2017), 721–728.
9. Rosenstock, J., Frias, J., Páll, D., et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab 20 (2018), 520–529.
10. Dagogo-Jack, S., Liu, J., Eldor, R., et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab 20 (2018), 530–540.
11. Hollander, P., Liu, J., Hill, J., et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study. Diabetes Ther 9 (2018), 193–207.
12. Pratley, R.E., Eldor, R., Raji, A., et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metab 20 (2018), 1111–1120.
13. US Food and Drug Administration, Steglatro™ (ertugliflozin) prescribing information. 2017, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
14. European Medicines Agency, Steglatro™ (ertugliflozin) summary of product characteristics. 2018, Merck Sharp & Dohme Ltd.
15. Zinman, B., Inzucchi, S.E., Lachin, J.M., et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol, 13, 2014, 102.
16. Fitchett, D., Zinman, B., Wanner, C., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 37 (2016), 1526–1534.
17. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Optimizing the analysis strategy for the CANVAS program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 19 (2017), 926–935.
18. Mahaffey, K.W., Neal, B., Perkovic, V., et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (canagliflozin cardiovascular assessment study). Circulation 137 (2018), 323–334.
19. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
20. Bhatt, D.L., Fox, K.A.A., Hacke, W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006), 1706–1717.
21. McMurray, J.J., Gerstein, H.C., Holman, R.R., et al. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2 (2014), 843–851.
22. Gilbert, R.E., Krum, H., Heart failure in diabetes: effects on anti-hyperglycaemic drug therapy. Lancet 385 (2015), 2107–2117.
23. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
24. Marx, N., McGuire, D.K., Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J 37 (2016), 3192–3200.
25. Heerspink, H.J., Perkins, B.A., Fitchett, D.H., et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 (2016), 752–772.
26. Ferrannini, E., Mark, M., Mayoux, E., CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
27. Taegtmeyer, H., Failing heart and starving brain: ketone bodies to the rescue. Circulation 134 (2016), 265–266.
28. Sattar, N., McGuire, D.K., Pathways to cardiorenal complications in type 2 diabetes mellitus: a need to rethink?. Circulation 138 (2018), 7–9.
29. Inzucchi, S.E., Zinman, B., Fitchett, D., et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41 (2018), 356–363.
30. Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., et al. Dapagliflozin a glucose lowering drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15 (2013), 853–862.